Australia's Antisense Therapeutics rises on positive trial data for drug

Percheron Therapeutics

14/03/2022 03:12

** Shares of drug developer Antisense Therapeutics Ltd
 ANP.AX  rise as much as 12% to A$0.140, marking their biggest
intraday pct gain since Feb. 25
    ** Co says new trial data supports potential of its ATL1102
drug improving bone density in Duchenne Muscular
Dystrophy urn:newsml:reuters.com:*:nASXb8c02w
    ** Stock hits highest since March 3
    ** Stock down ~36% YTD as of last close

 (Reporting by Arundhati Dutta in Bengaluru)
 ((Arundhati.Dutta@thomsonreuters.com;))